← All trials
NCT06742723
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 3, 2025
- Primary completion
- Apr 18, 2030
- Completion date
- Apr 18, 2030
- First posted
- Dec 19, 2024
- Last posted
- Dec 19, 2024
- Enrollment
- 5000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AstraZenecaLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.